Renaissance Group LLC boosted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,731 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,291 shares during the quarter. Renaissance Group LLC owned 0.18% of Jazz Pharmaceuticals PLC worth $15,756,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Toronto Dominion Bank boosted its stake in shares of Jazz Pharmaceuticals PLC by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the period. US Bancorp DE boosted its stake in shares of Jazz Pharmaceuticals PLC by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the period. Gargoyle Investment Advisor L.L.C. purchased a new position in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $206,000. Advisor Group Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC by 62.4% in the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after buying an additional 550 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $211,000. Institutional investors own 90.52% of the company’s stock.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up $0.92 during trading hours on Wednesday, hitting $137.19. The stock had a trading volume of 341,000 shares, compared to its average volume of 513,874. The firm has a market capitalization of $8,169.46, a price-to-earnings ratio of 17.10, a P/E/G ratio of 0.81 and a beta of 1.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. Jazz Pharmaceuticals PLC has a 1-year low of $99.28 and a 1-year high of $163.75.
Several brokerages have recently issued reports on JAZZ. UBS AG decreased their price objective on Jazz Pharmaceuticals PLC from $172.00 to $168.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Janney Montgomery Scott reiterated a “buy” rating and issued a $192.00 price objective (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Morgan Stanley began coverage on Jazz Pharmaceuticals PLC in a research note on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 price objective for the company. Deutsche Bank AG set a $175.00 price objective on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $180.13.
WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Shares Bought by Renaissance Group LLC” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://sportsperspectives.com/2017/11/22/jazz-pharmaceuticals-plc-jazz-shares-bought-by-renaissance-group-llc.html.
In other news, Director Patrick G. Enright sold 352 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the transaction, the director now owns 1,365 shares of the company’s stock, valued at $181,804.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The disclosure for this sale can be found here. In the last three months, insiders sold 10,703 shares of company stock worth $1,469,851. Corporate insiders own 4.30% of the company’s stock.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.